By John Vandermosten, CFAOTCQX:DYAIREAD THE FULL DYAI RESEARCH REPORTINITIATING COVERAGEWe are initiating coverage of Dyadic International Inc. (OTCQX:DYAI) with a $4.50 price target based on our estimates for commercialization of the company’s proprietary C1 technology. C1 is a gene expression platform based on a fungus called Myceliophthora thermophila. The...
By John Vandermosten, CFANASDAQ:RXIIREAD THE FULL RXII RESEARCH REPORTOn October 3rd, 2018 RXi Pharmaceuticals Corp. (NASDAQ:RXII) announced it had closed its $15 million public underwriting. 3.725 million shares were issued at $0.70 per share and 17.702 million prefunded warrants were issued at $0.69 per share with a $0.01 exercise...
By David Bautz, PhDNASDAQ:MTFBREAD THE FULL MTFB RESEARCH REPORTBusiness UpdateMotif Bio Plc (NASDAQ:MTFB) is a biopharmaceutical company focused on the development of antibiotic compounds for difficult to treat bacterial infections. The company’s lead asset, iclaprim, is a novel diaminopyrimidine molecule that has completed Phase 3 testing for the treatment...
By David Bautz, PhDNASDAQ:MTPREAD THE FULL MTP RESEARCH REPORTBusiness UpdateMidatech Pharma Plc (NASDAQ:MTP) is a biotechnology company with three novel drug delivery technologies that all improve bio-distribution and bio-delivery of drugs. The technologies achieve this via either the targeted delivery, sustained release, or solubilized local delivery of existing therapeutic...
By David Bautz, PhDNASDAQ:VKTXREAD THE FULL VKTX RESEARCH REPORTBusiness UpdateVK5211 Phase 2 Results Presented at ASBMR 2018 Annual MeetingOn October 1, 2018, Viking Therapeutics, Inc. (NASDAQ:VKTX) announced that results from the Phase 2 clinical trial of VK5211 in patients with hip fracture were presented at the 2018 American Society...
By Brian Marckx, CFAOTC:PBSVREAD THE FULL PBSV RESEARCH REPORTLab Sale Improves Profitability, Further Bolsters Cash, Provides Strategic Options. Moving Price Target to $2.25/share…Pharma-bio Serv (OTC:PBSV) reported financial results for their fiscal third quarter ending July 31st. Revenue growth remains very robust, particularly as it relates to Puerto Rico and...
By David Bautz, PhDNASDAQ:CERCREAD THE FULL CERC RESEARCH REPORTBusiness UpdateCerecor, Inc. (CERC) is a fully integrated pharmaceutical company with a diversified offering of commercial products and a development product portfolio. The commercial portfolio consists of products intended to treat pediatric-focused conditions and includes the prescribed dietary supplements Poly-Vi-Flor® (a...
By John Vandermosten, CFANASDAQ:CORVCorrevio Pharma Corp. (NASDAQ:CORV) has had an exciting year for Brinavess so far in 2018. The asset was initially developed by Correvio’s predecessor company Cardiome starting in 1986 and bought by Merck for further development after completing Phase III studies in 2009. While it received EMA...
By Brian Marckx, CFANASDAQ:EYEGREAD THE FULL EYEG RESEARCH REPORTQ2 2018 Financial Results, Operating Update…EyeGate (NASDAQ:EYEG) reported Q2 2018 financial results and provided a business update. As it relates to the financials, Q2 included additional recognition of the milestone payments earned from Valeant. Through Q2, EYEG collected $13.5M from Valeant...
By David Bautz, PhDNASDAQ:MNOVREAD THE FULL MNOV RESEARCH REPORTBusiness UpdatePositive FDA Feedback Regarding Phase 3 ALS Development PlanOn September 25, 2018, MediciNova, Inc. (NASDAQ:MNOV) announced that the FDA provided positive feedback in regards to the company’s development plan for MN-166 (ibudilast) in amyotrophic lateral sclerosis (ALS). The FDA did...